Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PIVOINE: Palovarotene Rollover Study in FOP
NCT05027802Phase 3Completed
- Sponsor
- Ipsen
- Start
- Mar 2022
- Primary completion
- Nov 2024
- Modality
- Orthosteric Ligands
- Countries
- 10
01
Overview
A Phase 3 trial of palovarotene in fibrodysplasia ossificans progressiva (FOP), sponsored by Ipsen. Started Mar 2022; status: completed.
02
Drugs
palovarotene
03
Conditions
fibrodysplasia ossificans progressiva (FOP)
Beyond the preview
Go deeper on NCT05027802.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05027802.